Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals

U.S. drugmaker Eli Lilly has entered into an agreement to collaborate ​on and possibly licence experimental ‌medicines from a unit of Haisco Pharmaceutical Group , with potential payments of up to around $3 ​billion if milestones are met, ​the Chinese drugmaker said Monday.

Reuters • 19 hours ago

Eli Lilly Growing at 55% as a Trillion-Dollar Company: ‘These Are NVIDIA-Like Growth Numbers'

Macro strategist Jordi Visser delivered a striking observation on a recent episode of The Pomp Podcast with Anthony Pompliano.

24/7 Wall Street • 15 hours ago

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease These data will be published in the New England Journal of Medicine and simultaneously presented during the Plenary Session at the 2026 ASCO Annual Meeting INDIANAPOLIS, May 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) with selpercatinib reducing the risk of disease recurrence or death by 83% versus placebo in the primary analysis population.

PRNewsWire • May 31, 2026

Invesco Summit Fund Q1 2026 Portfolio Update

At quarter end, Invesco Summit Fund's largest overweights were in industrials, energy and communication services. Within industrials and energy, AI related energy demand has continued to drive spending on electrical infrastructure and power generation. The largest underweight was consumer discretionary, reflecting higher inflation from the US/Israel war with Iran and potential AI related employment pressure.

Seeking Alpha • May 31, 2026

Stock Split Watch: Is Eli Lilly Next?

Eli Lilly stock has climbed in the triple-digits in recent years and just topped $1,000. The company is firing on all cylinders in the high-growth weight loss drug market.

The Motley Fool • May 30, 2026

Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors

The market for GLP-1 drugs is large and attractive, with Eli Lilly currently an industry leader. Competition in the drug industry is fierce, with Eli Lilly already working on a more effective GLP-1 option.

The Motley Fool • May 30, 2026

Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients

We also report on two studies with findings that could bring eventual relief for patients still struggling with ​long COVID symptoms.

Reuters • May 29, 2026

Eli Lilly Breaks Out Amid Vaccine Push; Three More Stocks At Highs

Eli Lilly is near an all-time high in Friday's stock market after a strong first-quarter report. Shares are below a 1133.95 pivot.

Investors Business Daily • May 29, 2026

LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?

Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.

Zacks Investment Research • May 29, 2026

CVS brings back coverage for Lilly's obesity drug Zepbound

CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some of its ​drug lists as an additional preferred option for insurance coverage.

Reuters • May 28, 2026